News
Article
March 31, 2025
Author(s):
Fact checked by:
Conference|EBMT Meeting
Listen
Key Takeaways
Ciltacabtagene autoleucel led to prolonged PFS in patients with significant tumor burden reduction before lymphodepletion in the CARTITUDE-4 trial.
Patients with a 25% or greater tumor burden reduction had higher PFS rates compared to those with less reduction.
SHOW MORE
Improved PFS was associated with at least a 25% reduction in tumor burden before treatment with cilta-cel in patients with relapsed/refractory multiple myeloma.
Newsletter
Stay up to date on the most recent and practice-changing oncology data
Subscribe Now!
Related Videos
Dr Olivia on the Phase 3 QuANTUM-Wild Trial of Quizartinib in Newly Diagnosed FLT3-ITD–Negative AMLDr Dholaria on Future Research Directions With P-BCMA-ALLO1 in R/R Multiple MyelomaDr Krishnan on T-Cell Therapies and Novel Targets Reshaping the Myeloma Treatment LandscapeDr Ali on Choosing Between CAR T-Cell Therapy and Bispecific Antibodies in R/R Multiple MyelomaDr Zonder on the Need for Increased Awareness in Multiple MyelomaDr Shah on Zamtocabtagene Autoleucel’s Favorable Safety Profile in R/R DLBCLDr Garfall on the Inclusion Criteria for a Study Evaluating Ide-Cel in Myeloma After Suboptimal Transplant/Maintenance ResponseDr Lee on the Antitumor Activity of Rinatabart Sesutecan in FRα+ Platinum-Resistant Ovarian CancerDr Lantsman on the Real-World Safety and Efficacy of Dostarlimab Plus Chemo in Endometrial CancerDr Westin on PFS Benefit With DUO-E Regimen Across Histologic and Molecular pMMR Endometrial Cancer Subgroups